Flexion Therapeutics Announces Podium Presentation of FX301 Preclinical Data at Virtual ANESTHESIOLOGY 2020 Meeting
- Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo
“These preclinical data showing that FX301 provided a sustained analgesic effect without motor impairment in a surgical pain model are particularly exciting as they highlight the potential of FX301 to address a significant unmet need in post-operative pain management,” said Scott Kelley, M.D., Chief Medical Officer of Flexion. “We are thrilled to share these findings in a podium presentation at the largest annual anesthesiology educational event and look forward to discussing the data with anesthesiologists from around the world.”
Highlights from the study include:
- FX301 provided both greater analgesic effect from 12 through 72 hours and a longer duration of effect through 72 hours compared to liposomal bupivacaine or placebo;
- Treatment with FX301 did not significantly affect total walking distance in animals at 2 and 24 hours post-injection; animals treated with liposomal bupivacaine experienced a significant reduction in total walking distance compared with baseline at 2 and 24 hours post-injection; and
- Systemic plasma profile of funapide, the active ingredient in FX301, remained relatively flat throughout the study, indicative of controlled drug release from the thermosensitive gel formulation, while high local concentrations of funapide were observed at the site of administration at 72 hours.
Flexion remains on track to file the Investigational New Drug (IND) application and initiate clinical trials in 2021.
FX301 is a locally administered NaV1.7 inhibitor product candidate, known as funapide, formulated for extended release in a thermosensitive hydrogel. The initial development of FX301 is intended to support administration as a peripheral nerve block for control of post-operative pain. Flexion believes FX301 has the potential to provide effective pain relief for three to seven days while preserving motor function and anticipates initiating clinical trials in 2021.
This release contains forward-looking statements that are based on the current expectations and beliefs of Flexion. Statements in this press release regarding matters that are not historical facts, including, but not limited to, statements relating to the future of Flexion; expected regulatory and clinical developments and timelines; and the potential therapeutic and other benefits of FX301, are forward-looking statements. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the fact that the impacts and expected duration of the COVID-19 pandemic are uncertain and rapidly changing; the risk that additional preclinical and other data may not support initiation of clinical trials; the risk that we may not be able to maintain and enforce our intellectual property, risks related to clinical trials, including potential delays, safety issues or negative results; risks related to key employees, markets, economic conditions, and health care reform; and other risks and uncertainties described in our filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended
Source: Flexion Therapeutics, Inc.